Jon Garfield - BWV Chief Officer
| BWV Etf | USD 1.12 0.04 3.45% |
| Age | 59 |
| Phone | 513 620 4101 |
| Web | https://www.bluewatervaccines.com |
Jon Garfield Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jon Garfield against BWV etf is an integral part of due diligence when investing in BWV. Jon Garfield insider activity provides valuable insight into whether BWV is net buyers or sellers over its current business cycle. Note, BWV insiders must abide by specific rules, including filing SEC forms every time they buy or sell BWV'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jon Garfield over a year ago Acquisition by Jon Garfield of 100000 shares of Blue Water subject to Rule 16b-3 |
BWV Management Efficiency
The company has Return on Asset of (0.3022) % which means that on every $100 spent on assets, it lost $0.3022. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.0163) %, meaning that it generated no profit with money invested by stockholders. BWV's management efficiency ratios could be used to measure how well BWV manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| James JD | Allarity Therapeutics | 55 | |
| MPA MD | Unicycive Therapeutics | 52 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Jason Davis | Virax Biolabs Group | 53 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Robert McRae | Palisade Bio | N/A | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Timur Dogan | Cardio Diagnostics Holdings | 37 | |
| Brian Strem | Kiora Pharmaceuticals | 45 | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Steen Knudsen | Allarity Therapeutics | 64 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 36 | |
| James Foster | Virax Biolabs Group | 40 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| John CPA | Unicycive Therapeutics | 63 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Chester III | Revelation Biosciences | 45 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
Management Performance
| Return On Equity | -1.02 | |||
| Return On Asset | -0.3 |
BWV Money Managers
| Theodore Yoho, Head Devel | ||
| Erin Henderson, Chief Sec | ||
| Brian Price, Head Strategy | ||
| Andrew Skibo, Global Operations | ||
| Jon Garfield, Chief Officer | ||
| MBA MS, Pres CEO | ||
| Ronald Cobb, Head Discovery |
BWV Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is BWV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.02 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | 8.81 M | |||
| Shares Outstanding | 18.66 M | |||
| Shares Owned By Insiders | 17.69 % | |||
| Shares Owned By Institutions | 23.44 % | |||
| Number Of Shares Shorted | 23.33 K | |||
| Price To Book | 0.35 X | |||
| EBITDA | (13.54 M) | |||
| Net Income | (13.42 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
The market value of BWV is measured differently than its book value, which is the value of BWV that is recorded on the company's balance sheet. Investors also form their own opinion of BWV's value that differs from its market value or its book value, called intrinsic value, which is BWV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BWV's market value can be influenced by many factors that don't directly affect BWV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BWV's value and its price as these two are different measures arrived at by different means. Investors typically determine if BWV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BWV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.